![]() Induction chemotherapy consisted of R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone) in 19 patients and R-CVAD (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in 1. Patients were eligible for ASCT if they fulfilled the following criteria: Bone marrow biopsy was taken at diagnosis and then repeated at the time of transplant. The diagnostic work-up included physical examination, blood and serum analysis, chest X-ray, and computed tomography of the neck, chest, abdomen and pelvis. The disease stage was evaluated according to the Ann Arbor staging system and the International Prognostic Index for Mantle Cell Lymphoma (MIPI) score was calculated as published elsewhere. A histological diagnosis was established by the local pathologist and overexpression of Cyclin D1 was confirmed by immunochemistry in all patients. The management of patients after diagnosis followed common standards, but due to the fact that some patients were referred for transplantation from other centres, not all data were available for all patients. ![]() Twenty patients (7 male and 13 female) at median age of 59 years (41–68 years) received ASCT in our centre between 20. ![]() Herein we report the outcome of ASCT performed in our centre for twenty patients diagnosed with MCL. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may increase progression-free (PFS) and overall survival (OS), but survival curves do not eventually plateau. Mantle cell lymphoma remains incurable with conventional chemotherapy and responses are short-lived. The clinical course of MCL becomes aggressive with time and resistant to chemotherapy with a median survival of 3 to 5 years. Most patients have an advanced stage of disease at diagnosis with common extranodal involvement including bone marrow, spleen, liver and gastrointestinal tract. Mantle cell lymphoma is more frequently seen in males than in females (2: 1), with a median age of 60 to 65 years. The t(11 14)(q13 q32) between and cyclin D1 genes is thought to be the primary genetic event in the pathogenesis of MCL. Mantle cell lymphoma (MCL) is a B-cell neoplasm characterized by monomorphic proliferation of small and medium-sized lymphoid cells expressing mature B-cell markers and IgM and/or IgD surface immunoglobulin. Ten patients died from disease recurrence and subsequent chemoresistance. After median follow-up after ASCT of 36 months (range 11–73), 10 patients were alive with 8 remaining in complete remission (CR) whereas 2 relapsed and received salvage chemotherapy. The estimated 5-year OS and PFS were found to be 52% and 35%, respectively. Median OS and PFS were 48 and 29.8 months, respectively. The transplant-related mortality was 0% at day 100. The conditioning regimen prior to ASCT consisted of CBV and BEAM for 18 and 2 patients, respectively. The disease status at transplant was as follows: first complete response ( n = 13) second complete response ( n = 4) and partial response ( n = 3). Induction chemotherapy consisted of the R-CHOP regimen in all patients except one who received R-CVAD. 90% of transplanted patients had stage III/IV disease at diagnosis and low, intermediate and high MIPI scores occurred in 5, 9 and 6 patients respectively. Twenty patients (7 male and 13 female) at median age of 59 years (range 41–68) were included.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |